Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Cited by CrossRef (6)

  1. Min Li, Tadayuki Oshima, Tomoki Horikawa, Katsuyuki Tozawa, Toshihiko Tomita, Hirokazu Fukui, Jiro Watari, Hiroto Miwa. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori . Helicobacter 2018;23:e12495
    https://doi.org/10.1111/hel.12495
  2. Hideki Mori, Hidekazu Suzuki. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil 2019;25:6
    https://doi.org/10.5056/jnm18139
  3. Carmelo Scarpignato, Richard H. Hunt. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344
    https://doi.org/10.1097/MOG.0000000000000543
  4. Prashanth Rawla, Tagore Sunkara, Andrew Ofosu, Vinaya Gaduputi. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?. WJGPT 2018;9:63
    https://doi.org/10.4292/wjgpt.v9.i7.63
  5. Tadayuki Oshima, Eitatsu Arai, Masato Taki, Takashi Kondo, Toshihiko Tomita, Hirokazu Fukui, Jiro Watari, Hiroto Miwa. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019;49:140
    https://doi.org/10.1111/apt.15062
  6. Marc Bardou, Kyle J. Fortinsky, Nicolas Chapelle, Maxime Luu, Alan Barkun. An update on the latest chemical therapies for reflux esophagitis in children. Expert Opinion on Pharmacotherapy 2019;20:231
    https://doi.org/10.1080/14656566.2018.1549224